Seagen Inc.
https://www.seagen.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Seagen Inc.
Keeping Track: Idorsia’s Quviviq Is FDA’s First Novel Approval Of 2022; AbbVie’s Rinvoq Gains Eczema Claim
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
EU New Drug Approvals Hit Record High
Chaos wrought by the ongoing coronavirus pandemic. A heavy workload and continuing resource constraints at the European Medicines Agency. Nonetheless, a record number of novel drugs and vaccines were cleared for marketing in the EU last year.
Oncology Dominates China's 43 New Approvals In 2021, Domestics Emerge To Lead Innovation
Out of the more than 40 approvals granted to new drugs in China in 2021, domestic companies bagged around half to catch up with their multinational peers in the annual innovation scorecard.
Argenx Takes Slow But Steady Approach To Vyvgart Sales
Despite a US approval for its novel FcRn inhibitor Vyvgart in gMG, the firm has realistic expectations of sales, factoring in concerns about COVID-19 and lagging medical education.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Alpine Biosciences
- Biomira
- Oncothyreon, Inc.
- Cascadian Therapeutics, Inc.
- Seattle Genetics, Inc.